Revance Therapeutics Inc (RVNC.OQ)
23 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2014||Independent Chairman of the Board|
|55||Co-Founder, President, Chief Executive Officer, Director|
|58||2015||Chief Financial Officer, Chief Business Officer|
|54||2015||Chief Operating Officer|
|2018||Vice President of Strategy and Sales|
- CORRECTED-Mylan teams up with Revance on biosimilar for Botox
- BRIEF-Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14
- BRIEF-Revance Therapeutics, Mylan Ireland Enter Collaboration Deal
- BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis
- BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018